Tirzepatide (Mounjaro) and Semaglutide (Wegovy or Ozempic) are two of the most popular medications in this class, offering significant benefits for patients looking to achieve sustainable weight loss and better metabolic health
It belongs to a novel class of drugs known as triple agonists , meaning it simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1) which reduces appetite and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) which may enhance insulin secretion and has been suggested in early studies to support fat metabolism Glucagon receptor which may increase energy expenditure and has been proposed to support fat breakdown in the liver, based on early pharmacological data [11] [12] This triple mechanism distinguishes retatrutide from existing approved medicines such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
It also creates a larger upfront commitment
Clinical Evidence for GLP-1s in Seniors Retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, is currently in Phase 3 trials with no FDA approval yet
Conveniently, I'm never very hungry now, and haven't eaten a heavy meal in over a month
In just under a year
